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quinolone prophylaxis has been used indiscriniinately in low- and 
high-risk patients and this has been a mistake. Future approaches 
should select patient populations that are more likely to benefit from 
prophylaxis. 
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[s107] Prevention and treatment of CMV infection in 
stem cell transplant recipients: strategies and 
challenges 
P. Keusser. Departwimt .f Medicine, Chiversify Hospital, Basel, 
Switzerland 
Patients after stem cell transplantation (SCT) are at increased risk for 
cytoniegalovirus (CMV) infection and serious CMV disease during 
the period of profound immunodeficiency early after transplantation. 
In recent years, efficient strategies for the management of CMV 
infection and disease in SCT recipients have been developed. Progress 
was made possible by the introduction into clinical use of rapid and 
sensitive diagnostic methods and of potent antiviral drugs against 
CMV Primary CMV infection is best prevented by the exclusive use 
of seronegative or leukocyte-depleted blood products if the stem cell 
donor is CMV seronegative. CMV disease due to reactivation of 
latent virus can be prevented by preemptive treatment of CMV 
infection with intravenous ganciclovir. but this drug is associated with 
important marrow toxicity. If the initiation of treatment i5 based on 
positive CMV antigeneniia or P C R  in peripheral blood specimens, 
which are methods that detect CMV infection at an earlier stage than 
the shell-vial assay, the duration of  ganciclovir niay be shortened, 
thereby reducing the risk of severe neutropenia. Foscarnet, which is 
equally effective against CMV hut which lacks niajor bone inarrow 
toxicity, niay prove to be a valuable alternative in the preemptive 
treatnic'nt of CMV infection after SCT. A randomized coinparison 
of foscarnet and ganciclovir for preemptive treatment of CMV 
infection was recently concluded among the centers of the European 
Group for Blood and Marrow Transplantation (EBMT), and reqults 
of this trial should become available soon. Prophylaxis of CMV 
infection after SCT is also carried out by using high-dose intravenous 
acyclovir, which was shown to he safe but only partially effective in 
preventing CMV disease in these patients. A recent study of 
valaciclovir prophylaxis for CMV infection after allogeneic SCT 
showed a significant reduction of CMV vireniia but no difference in 
the incidence of CMV disease or in the mortality when coinpared 
to acyclovir prophylaxis. The role of passive iinrnunization in the 
prevention of CMV infection and disease after SCT remains contro- 
versial, and in view of the unclear benefit and of the important costs 
of immune globulin infusions, this approach cannot be advocated for 
routine use without further investigations. The  therapy of established 
CMV piieumonia after SCT currently consists of combining 
ganciclovir with high-dose intravenous irninune globulins, which 
induces a treatment response in approximately 60'% of patients, but 
the long-term survival rate is only about 3tI% Thus, iiiajor emphnsis 
must be placed on preventing CMV disease in SCT recipients. The  
emergence of CMV strains resistant to antiviral drug treatment is 
being reported with increasing frequency and is of concern. The  
incidence and best alternative therapy of disease due to resistant CMV 
after SCT need to be determined. Future studies niay furthermore 
help to clarify the role of novel antiviral agents, such as cidofovir, 
valganciclovir, lobucavir, and the derivative of compound 1263W9.1, 
in the prevention and preeniptive treatment of CMV infection in 
patients after SCT. Moreover, new approaches to prevention ofCMV 
infection, such as adoptive inimunotherapy with CMV-specific 
cytotoxic T-lymphocyte clones, need to be further investigated. 
HSV and VZV infection in 
immunocompromised patients 
M. Hoeckh. Fed  Hirtr/riir.wn Caiiccr Rcs. G i w q  l~$rrti~ins Di.reuscs, 
Scatrlc, 12:4, USA4 
Major progress has been mads in thc m~ir,~gcment of HSV and VZV 
infections in ininiunvcoiiiproniised patients over the List 15 years. In  
transplant patients, especially niarrow transplant recipirnts, acyclovir 
prophylaxis IS now routinely given to HSV-seropositive rccipieiit\. 
Thi\ has virtually eliminated serious complications of HSV infections 
during the period of highest risk of reactivation. However, recurrent 
HSV infection continues to occui. after discontinuation of acyclovir, 
mainly in patients with continued inimutiosuppression. Recurrent 
HSV infection inay be associated with developiiient of drug 
resistance. Foscarnet has been used successfully 111 cases of acyclovir 
resistance. VZV infections are coiiiinon in both transplant and HIV- 
infected patients, Treatment with high-dose acyclovir is usually 
successful, but cases with fatal or complicated outconies continue to 
occur, especially when the clinical presentation is atypical and/or 
treatment is instituted late during the course. Such clinical situations 
include abdominal presentations without skin lesions after niarrow 
transplantation. This overview will discuss current issues of HSV and 
VZV infections in iinniunocomprotiii\ed patients, including the 
recent epidemiology in transplant recipients and HIV-infected 
patients receiving potent antiretroviral therapy, clinical nianifest- 
ations, immunobiology, diagnosis, pharrnacologic agents, drug re\ist- 
ance, immunization, and current prevention and treatment strategies. 
Next generation quinolones for a new 
therapeutic millennium 
ISlll( Structural determinants of quinolone potency 
and bacterial resistance 
D.C. Hooper. dlnrsar/lrrsctts Genenil Hospitnl, Boston, hL4, C7S.4 
The potency of the quinoloncs is detemmined by their activity in 
stabilizing DNA complexes with DNA gyrase and topoisomerase IV, 
bacterial enzymes with distinct and essential role\ in DNA cynthesis, 
and by their ability to permeate cell nienibraiies and avoid eRlux to 
reach these targets. Potency also affects the ritk of development of 
bacterial resistance. For quinolones with a high therapeutic index, 
selection of mutants at clinically relevant concentratioiis may he low. 
Resistance may decrease for quinolones with balanced activity against 
both target enzymes and for those that are poor substrates for bacterial 
iiiultidrug eff7ux puiiips. The activity of quinohnrs again\t Grant- 
negative bacteria is enhanced by the addition of a fluorine a t  po\ition 
6 and J piperazine at position 7. The cyclopropyl group a t  pwition 
3 also enhances potency Other quinolone modifications haw led to 
the newest agents with enhanced activity againft Gram-positivc 
pathogens and anaerobes and preserved potency against Gram- 
negative bacteria. Improvement of Grain-pos~tive activity 111 \o~i ie  
cases correlates with enhanced potency against topoironierase IV 
Potency is increased by alkylation of the pipcrziiiyl group or 
substitution of I? pyrrolidinyl group a t  position 7, amino or methyl 
subqtituents at position 5, and halides or inethoxy groups at po\ition 
8. These latter substituents also improve maerobic activity. The latect 
generation of quinolones with such changes have fiirther iiiiproved 
potency and breadth of spectrum, rivaling those of carhapenem\. 
These modifications also result in compounds with iiiore closely 
balanced activities against DNA gyrase and topoisonierasc IV and 
some with substantially lower frequencies of resistance in vitro. It 
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remains to be determined ifthese advantages in vitro can be translated 
into reduced risk of development of quinolone resistance in clinical 
use. 
m] Comparative activity of clinaftoxacin against 
Gram-positive and Gram-negative bacteria 
P.C. Appelbaum. Hershey Medical Centeer, Dept.c$Patho/ogy, Hershey, 
PA, USA 
Standardized agar dilution was used to compare the activity of clina- 
floxacin, ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin, 
piperacillin, piperacillin/tazobactam, trimethoprim-sulfameth- 
oxazole, ceftazidime. and imipenem against 354 Gram-negative non- 
fermenters, Enterobacteriaceae, streptococci and staphylococci. 
Organisms included 143 ciprofloxacin-susceptible strains (MIC 
< = 1 .0 mg/L) and 21 1 strains with raised ciprofloxacin MICs 
(=2.0 mg/L). Clinafloxacin yielded the lowest MICs of all quino- 
lones tested, with MICs < =0.5 mg/L against ciprofloxacin- 
susceptible and MICd < = 16.00 mg/L against ciprofloxacin-inter- 
mediate and -resistant Gram-positive and -negative organisms. By 
comparison, MICs of levofloxacin, trovafloxacin and sparfloxacin 
were < =2.0 mg/L against ciprofloxacin-susceptible strains, with 
many ciprofloxacin-resistant organisms yielding MICs of 32 mg/L for 
all three quinolones. Among ciprofloxacin-resistant strains, clina- 
floxacin, levofloxacin, spariloxacin and trovafloxacin were generally 
most active against Stenotrophomonas maltophilia (MICs< =4.0 mg/L) 
and Srreptucuccm pneumoniue (MICs < =2.0 mg/L). Ceitazidme, 
piperacillin + tazobactam and trimethoprimsulfamethoxazole yielded 
higher MICs against ciprofloxacin-resistant compared to ciprofloxacin- 
susceptible Gram-negative non-fermenters. Enterobacteriaceae and 
Enterorocrusfaecium also yielded high MICs against these compounds. 
Imipenem resistance was only seen in Gram-negative non- 
fermenters, methicillin-resistant Staphylococcus uureus and enterococci. 
Clinafloxacin shows promise for treatment of infections caused by 
ciprofloxacin-resistant organisms. 
Time-kill tests were used to test possible synergy between 
clinafloxacin and a variety of other agents against 44 Gram-negative 
and -positive bacteria, most with clinafloxacin MICs being 1 mg/L. 
When synergy was considered at 6 h, 12 h, and 24 h, clinafloxacin 
was synergistic with ceftazidime, amikacin and imipenem against: 
2/3, 2/3, 3/3 Pseudomonas aeruginosa; 3/3, 013, 1/3 Stenotrophomonas 
maltophilia; 2/3, 3/3, 3/3 Acinetobacter spp; 3/3, 2/3, 3/3 Burkholderia 
cepaciu; 0/3, 2/3, 1/3 Escherickiu coli; 1/3, 1/3, 1/3 Klebsiella 
pneumuniae; 1/3, 113,013 Enterobactercloacae; 3/3,3/3,3/3 Citrobacter 
jeundii; 3/3, 3/3, 2/2 Serratia marcescens; 2/2, 212, 2/2 Dtovidencia 
stuartii; 1/1, 0/1, 011 Morganella murganii. Among Gram-positive 
bacteria, clinafloxacin showed synergy with vancomycin, teicoplanin, 
cefotaxime and vancomycin in: 2/3, 3/3, 3/3, 2/2 methicillin- 
resistant Staphylococcus nureus; 1 /3, 1/3, 113, 0/3 Enterococcus/aecalis; 
1/3, 1/3, 1/3, 1/3 Enterocuccusfaecium (the only strain with a low 
clinafloxacin MIC of 0.25 mg/L). Against pneumococci, clina- 
floxacin showed synergy with vancomycin, penicillin G, cefotaxime 
and synercid in 013, 2 / 3 ,  213, and 0/3 strains. In all cases of synergy, 
clinafloxacin MICs were lower than those obtained with the drug 
alone, and, in most cases, subinhibitory levels of the accompanying 
drug were also found. 
Is113) Surgical infections: clinical options for 
diagnosis and treatment 
C.E. Nord. University Hospital, Dept. of Immunolofl, Huddinge, 
Sweden 
Intra-abdominal infections are a common and serious clinical 
problem, particularly in general surgery and surgical intensive care 
units. These infections are nearly always polymicrobial in nature, 
involving both aerobic and anaerobic pathogens. Treatment usually 
includes drainage, intensive care and administration of broad- 
spectrum antimicrobial agents. Computerized tomography is an 
important tool for evaluating patients suspected of having an intra- 
abdominal infection, and for guided aspiration of suspected intra- 
abdominal abscesses. Antimicrobial agents must penetrate to the 
infection site in concentrations sufficient to overcome the effects of 
a number of factors that may lower the drug’s activity, including high 
bacterial density, metabolic inactivity and slow growth rate of the 
bacterial inoculum, low pH, very low oxygen tension, and necrotic 
tissue. Quinolones are potent broad-spectrum antimicrobials with 
rapid bactericidal activity that have been used successfully in the 
treatment of a variety of infections. Older quinolones such as cipro- 
floxacin possess excellent activity against Gram-negative bacteria, 
good activity against Gram-positive bacteria, and poor activity against 
anaerobes. Ciprofloxacin in combination with an anti-anaerobic 
agent has shown good efficacy in the treatment of intra-abdominal 
infection. The availability of newer quinolones with enhanced 
activity against anaerobes as well as Gram-positive bacteria makes 
treatment of intra-abdominal infections a possibility. Of these newer 
agents, clinafloxacin has been shown to be active against many 
pathogens that are commonly isolated from patients with intra- 
abdominal infections, including quinolone-resistant bacteria. Clinical 
data with this agent are encouraging, and the results from ongoing 
intra-abdominal infection trials are awaited with interest. 
Exotoxi ns 
Toxins with intracellular actions 
K. Aktories. Uniuersitiit Freiburg, Pharmakolog. Institut, Freiburg, 
Germany 
At least four distinct steps are involved in the effects of bacterial 
protein toxins acting inside eukaryotic target cells, including: (1) 
binding of the toxin to the target cell membrane, (2) internalization 
of the bound toxin, (3) translocation into the cytosol, and (4) 
modification of the intracellular target. Studies fkom recent years have 
greatly increased our knowledge of these processes. Most remarkable 
has been the progress in respect to structure-function analysis of the 
toxins, identification of novel eukaryotic toxin substrates and the 
understanding of the molecular mechanisms by which toxins mohfy 
their eukaryotic targets. These advances have depended on successful 
crystal structure analyses of toxins and the application of cell- 
biological methods, inaugurating a novel field of a cellular micro- 
biology. Recent advances in the understanding of toxins acting on 
the cytoskeleton will be discussed in detail. 
